FDA Approves New Glucose Monitoring App for Data-Sharing Among Diabetic Patients and Caregivers

The US Food and Drug Administration (FDA) allowed marketing of the first set of mobile medical apps that allow diabetics to automatically and securely share data from a continuous glucose monitor (CGM) with other people in real-time.

The Dexcom Share Direct Secondary Displays system’s data-sharing capability allows diabetes patient caregivers to monitor an individual’s blood sugar levels remotely. Other CGMs are also available on the market, however Dexcom Share is the first to receive the FDA’s approval.

The app allows caregivers and families to keep an eye on a diabetes patient’s glucose levels remotely, in order to avoid complications, such as hyperglycemia. The Dexcom Share involves two apps, one which would be downloaded by the patient, who will be able to set up “followers” that can view their information and the second would be downloaded by the caregiver to view the CGM data in real time. The patient can share data with up to five followers.

The system includes a small, wire-like sensor which a patient would insert just under the skin. The device continuously transmits data to a monitor that is worn externally. When used along with a blood glucose meter, CGM information can help diabetes patients detect when blood glucose values are approaching dangerously high and dangerously low levels.

“This innovative technology has been eagerly awaited by the diabetes community, especially caregivers of children with diabetes who want to monitor their glucose levels remotely,” said Alberto Gutierrez, PhD, director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health. “Today’s marketing permission paves the way for similar technologies to be marketed in the United States.”

Dexcom said that it anticipates to ship the Share receiver to new patients in March. This is the first Dexcom system that is mobile compatible without the use of a docking system.

The app was approved under the FDA’s de novo process, which was created for low- to moderate-risk devices, which doesn’t require the same review process as more complicated products. It is the first to receive regulatory approval for US sales since the FDA began regulating mobile medical apps as devices in 2013.

“The Dexcom Share receiver represents a significant step forward for our company and our mobile strategy, but more importantly, it will provide a huge improvement for people managing their diabetes and for those parents and caregivers who help them each and every day,” said Kevin Sayer, President and Chief Executive Officer of Dexcom. “The FDA understands the importance of this type of innovation and the need to regulate it appropriately, and we could not be more pleased with the speed at which they reviewed and approved this important innovation.”

Sources: US Food and Drug Administration; DexCom, Inc.; Specialty Pharma Journal

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *